Simplex Trading’s Candel Therapeutics CADL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$198K Sell
40,400
-18,300
-31% -$99.6K ﹤0.01% 4310
2025
Q4
$332K Sell
58,700
-26,100
-31% -$140K ﹤0.01% 3712
2025
Q3
$432K Buy
84,800
+8,400
+11% +$48.5K ﹤0.01% 4003
2025
Q2
$386K Buy
76,400
+29,600
+63% +$152K ﹤0.01% 3786
2025
Q1
$264K Sell
46,800
-14,000
-23% -$114K ﹤0.01% 4045
2024
Q4
$527K Buy
60,800
+59,000
+3,278% +$349K ﹤0.01% 3484
2024
Q3
$12K Buy
1,800
+1,600
+800% +$9.94K ﹤0.01% 7049
2024
Q2
$1K Buy
+200
New +$1.5K ﹤0.01% 8427

Other funds holding CADL

Simplex Trading's CADL Position: Q1 2026 in Review

Simplex Trading opened a new position in Candel Therapeutics (CADL) in Q1 2026: 13,216 shares worth $64.8K. The stake represents ﹤0.01% of the portfolio and ranks #5576 among its holdings. This is a return to the name: Simplex Trading previously reported a position in CADL as recently as Q1 2025.

Simplex Trading first reported a position in CADL in Q2 2024 and has held it in 5 quarters since. The position peaked at $158K in Q3 2024. 114 funds tracked by Wall St. Rank hold CADL as of Q1 2026.

  • Simplex Trading held 13,216 shares of Candel Therapeutics worth $64.8K as of Q1 2026.
  • Candel Therapeutics was a new Simplex Trading position in Q1 2026.
  • Candel Therapeutics made up ﹤0.01% of Simplex Trading's portfolio in Q1 2026, its #5576 holding.
  • Simplex Trading first reported a position in Candel Therapeutics in Q2 2024 and has held it in 5 quarters since.
  • Simplex Trading's Candel Therapeutics position peaked at $158K in Q3 2024.
  • 114 funds tracked by Wall St. Rank held Candel Therapeutics as of Q1 2026.

Based on Simplex Trading's 13F filing for Q1 2026, filed 14 May 2026.